Vitrakvi FDA Approval History
Last updated by Judith Stewart, BPharm on Nov 26, 2018.
FDA Approved: Yes (First approved November 26, 2018)
Brand name: Vitrakvi
Generic name: larotrectinib
Dosage form: Capsules and Oral Solution
Company: Loxo Oncology, Inc.
Treatment for: TRK Fusion Cancers
Vitrakvi (larotrectinib) is an oral selective tropomyosin receptor kinase (TRK) inhibitor for the treatment solid tumors harboring NTRK-fusion proteins.
- Research suggests that the NTRK genes can become abnormally fused to other genes, producing a TRK fusion protein that can lead to the development of solid tumors across various sites of the body.
- Examples of tumor types with an NTRK fusion that responded to larotrectinib include soft tissue sarcoma, salivary gland cancer, infantile fibrosarcoma, thyroid cancer and lung cancer.
- The efficacy of larotrectinib was studied in three clinical trials that included 55 pediatric and adult patients with solid tumors that had an identified NTRK gene fusion. Larotrectinib demonstrated a 75 percent overall response rate across different types of solid tumors. These responses were durable, with 73 percent of responses lasting at least six months, and 39 percent lasting a year or more.
- Vitrakvi (larotrectinib) is taken orally twice daily.
- Common side effects (≥ 20%) reported by patients receiving Vitrakvi in clinical trials include fatigue, nausea, cough, constipation, diarrhea, dizziness, vomiting, and increased AST and ALT enzyme blood levels in the liver.
- Vitrakvi received an accelerated approval, which enables the FDA to approve drugs for serious conditions to fill an unmet medical need using clinical trial data that is thought to predict a clinical benefit to patients. Further clinical trials are required to confirm Vitrakvi’s clinical benefit.
Development timeline for Vitrakvi
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.